TO THE EDITOR Imatinib (Glivec s ) induces major cytogenetic responses in the vast majority of newly diagnosed CML patients. Most of these responses are durable, but a minority of patients progress to accelerated phase and eventually to blast crisis. Mechanisms causing this secondary resistance have been described and include mutations in the ATP binding site of Abl and amplification of genomic Bcr-Abl. 1 Here, we describe a CML patient who showed a remarkable clinical course on imatinib, developing blast crisis after having been in a complete cytogenetic response for more than 2 years. The bcr-abl transcript was aberrant, showing an insert of a 'kringle' domain of the Kremen-1 gene, which, to the best of our knowledge, has not been reported before.
A 27-year-old male with a previous history of gout was diagnosed with CML in July 2000. He had no siblings. There was no hepatosplenomegaly upon physical examination. The leukocyte count at diagnosis was 63 600/ml with 4% blasts and platelets of 455 000/ml. Cytogenetic examination revealed a t(9;22)(q34;q11) and a del9q þ in 100% of metaphases. Spleen diameter was 18 cm on ultrasound. The Hasford Euro-score was 2763, which classified the CML as high risk. Hydroxyurea treatment was started. After 3 weeks, he was recruited into the IRIS protocol, a randomized trial comparing interferon alpha plus low-dose cytarabine with imatinib. He was randomized to imatinib 400 mg daily, which led to a rapid hematological response with a partial cytogenetic response at 3 months (46XY, t(9;22)(q34;q11) [1] /46XY [28] ) and a complete cytogenetic response at 6 months. On quantitative PCR, the maximal reduction of bcr-abl transcripts in the peripheral blood was 2.77-log as measured 22 months after the start of imatinib therapy (bcr-abl/pbgd ratio of 1.6 Â 10
À3
). Good molecular response continued until July 2002. In January 2003 blood counts dropped with Hb 12.6 g/dl, platelets 182 000/ml and leukocytes 2500/ml with 3% blasts with vacuolated cytoplasm. A bone marrow aspirate was hypocellular, cytogenetic examination was, however, possible and showed remarkably normal karyotype in 28 metaphases, but both an additional Philadelphia chromosome and an extra chromosome 8 in two cells. Also, upon metaphase FISH, the abl signal was apparent both on the long and on the short arm of chromosome 9, implicating a duplication of the residual abl sequences on chromosome 9. Bcr-abl/pbgd ratio had increased with 5.8 Â 10 À2 in the peripheral blood and 3.5 Â 10 À1 in the bone marrow. Bone marrow histology showed a monotonous population of blast cells, positive for TdT, CD20, CD79a, CD10 and CD45, and negative for CD34, CD117, MPO, lysozyme and CD15, compatible with lymphoid blast crisis. Imatinib was stopped and he was consecutively treated with chemotherapy according to the ALL-84 protocol, consisting of induction with daunorubicin, vincristine, L-asparaginase and prednisone plus intrathecal methotrexate, two consolidation cycles with cytarabine plus intrathecal methotrexate and vincristine, cyclophosphamide and prednisone, respectively, followed by maintenance chemotherapy with mercaptopurine, methotrexate, daunorubicin, prednisone, vincristine and cyclophosphamide leading to a complete hematological remission. Unfortunately, a search for an unrelated stem cell donor was not successful. After 8 months after starting the induction chemotherapy, he receives maintenance treatment and is in continuous complete hematological remission. The latest PCR results showed a very low bcr-abl transcript level (bcr-abl/pbgd ratio of 2.2 Â 10 À5 in the peripheral blood and 4 Â 10 À5 in the bone marrow). The size of the bcr-abl transcript on conventional PCR is unchanged compared to that at diagnosis. Imatinib was restarted at a dose of 800 mg daily.
At diagnosis, multiplex PCR, performed according to the protocol of Cross, 2 showed an abnormally large product of around 550 bp (see Figure 1) . Automated sequencing and restriction enzyme analysis of the PCR-product at the time of blast crisis did not show any mutation in the tyrosine kinase catalytic domain of the bcr-abl gene, which is encoded by abl exons 4-9, 1 but both diagnosis and blast crisis PCR products revealed an insert of 261 bp, which was interposed between the bcr exon 2 and the abl exon 2. The sequence of the insertion is identical to a small part of the Kremen-1 gene that is normally located on chromosome 22q12.1. The Kremen-1 gene (GenBank Accession No. gi: 24041013) encodes a transmembrane receptor that, after binding of dickkopf homolog-1 (DKK1), blocks wingless (WNT)/beta-catenin signaling. 3 The insertion encodes a kringle domain, which is an extracellular domain of the Kremen-1 protein. Kringle domains are autonomous structural domains found in blood clotting and fibrinolytic proteins, some serine proteases and plasma proteins, and play a role in binding mediators (eg peptides), other proteins, membranes, or phospholipids. 4 This kringle insert was already present at diagnosis, meaning that the recombination event in chromosome 22 that had resulted in the insertion had taken place at an early phase of the disease. The second Philadelphia chromosome and trisomy 8 at blast crisis were, however, acquired during imatinib treatment. This implicates clonal evolution, which is frequently seen in the advanced phases of the disease, but is rarely encountered during imatinib treatment as well. 5 Although the patient attained complete cytogenetic remission rapidly and his molecular response was not different from many other patients receiving imatinib, 6 he suddenly developed blast crisis. Deletion of the derivative chromosome 9q has been reported to confer a bad prognosis in patients treated with interferon-alpha 7 and this probably also holds true for imatinib treated patients as was recently shown. 8 However, we can speculate on mechanisms, by which the kringle domain influenced Bcr-Abl function or the activity of imatinib. Firstly, it may be hypothesized that the binding capacity of the kringle domain to substrates influences the signaling properties of BcrAbl. Alternatively, the insertion may cause changes in the threedimensional structure of the Bcr-Abl protein that could result in a decreased binding of imatinib into the ATP-binding pocket of Abl. The unfavorable course of the disease in this CML patient may be related to these mechanisms. 
